HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18-positive patients: A prospective multicenter study with a 2-year follow up.
2‐year follow up
HPV 16/18 E7 oncoprotein
cervical intraepithelial neoplasia
high‐risk human papillomavirus
predictive value
triage effect
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
08 Sep 2024
08 Sep 2024
Historique:
revised:
19
08
2024
received:
19
06
2024
accepted:
27
08
2024
medline:
8
9
2024
pubmed:
8
9
2024
entrez:
8
9
2024
Statut:
aheadofprint
Résumé
To explore the effectiveness of HPV 16/18 E7 oncoprotein in detecting high-grade cervical intraepithelial neoplasia (CIN) and predicting disease outcomes in HPV 16/18-positive patients. The present study was a cross-sectional study with a 2-year follow up. We collected 915 cervical exfoliated cell samples from patients who tested positive for HPV 16/18 in gynecologic clinics of three tertiary hospitals in Beijing from March 2021 to October 2022 for HPV 16/18 E7 oncoprotein testing. Subsequently, 2-year follow up of 408 patients with baseline histologic CIN1 or below were used to investigate the predictive role of HPV 16/18 E7 oncoprotein in determining HPV persistent infection and disease progression. The positivity rate of the HPV 16/18 E7 oncoprotein assay was 42.06% (249/592) in the inflammation/CIN 1 group and 85.45% (277/324) in the CIN2+ group. For CIN2+ detection, using the HPV 16/18 E7 oncoprotein assay combined with HPV 16/18 testing, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 85.45%, 57.94%, 52.57%, and 87.95%, respectively. During the 2-year follow up, the sensitivity, specificity, PPV, and NPV for predicting persistent HPV infection were 48.44%, 58.21%, 34.64%, and 71.18% in the baseline inflammation and CIN1 group. As a triage method for high-grade CIN screening in HPV 16/18-positive patients, HPV 16/18 E7 oncoprotein demonstrated a relatively high NPV, making it suitable for clinical use in triaging HPV 16/18-positive cases and potentially reducing the colposcopic referral rate. HPV 16/18 E7 oncoprotein exhibited a preferably predictive value in determining HPV infection outcomes and disease progression.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National High Level Hospital Clinical Research
ID : 2022-PUMCH-C-031
Informations de copyright
© 2024 International Federation of Gynecology and Obstetrics.
Références
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890‐907.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first‐line screening test. Gynecol Oncol. 2015;136(2):189‐197.
Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk‐based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102‐131.
Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315‐324.
Kong L, Xiao X, Lou H, et al. Analysis of the role of the human papillomavirus 16/18 E7 protein assay in screening for cervical intraepithelial neoplasia: a case control study. BMC Cancer. 2020;20(1):999.
Xiao X, Cao Y, Bi K, et al. The triaging effect of the human papillomavirus 16/18 E7 Oncoprotein assay in HPV 16/18‐positive patients for high‐grade cervical intraepithelial neoplasia screening: a cross‐sectional study. J Women's Health. 2023;32(10):1136‐1141.
Kong L, Xiao X, Xu T, Wan R, Chen F. Immediate histologic correlation in patients with different HPV genotypes and ages: a single center analysis in China. BMC Cancer. 2023;23(1):1211.
Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880‐890.
Rezhake R, Chen F, Hu SY, et al. Triage options to manage high‐risk human papillomavirus‐positive women: a population‐based cross‐sectional study from rural China. Int J Cancer. 2020;147(8):2053‐2064.
Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513‐517.
Qiao YL, Jeronimo J, Zhao FH, et al. Lower cost strategies for triage of human papillomavirus DNA‐positive women. Int J Cancer. 2014;134(12):2891‐2901.
Zhang Q, Dong L, Hu S, et al. Risk stratification and long‐term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017;141(6):1110‐1119.
Rezhake R, Hu SY, Zhao S, et al. Eight‐type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV‐positive women. Int J Cancer. 2019;144(1):34‐42.
Wang X, Shuai G, Xu J, et al. HPV16 E7 oncoprotein test as a triage strategy for HPV16‐positive women in cervical cancer screening: long‐term follow‐up outcome. Front Oncol. 2023;13:1221962.